Cooperative Agreement U51PS000888

This Cooperative Agreement award in the amount of $1,900,000.00 was issued by the National Center for Emerging and Zoonotic Infectious Diseases, part of the U.S. Department of Health and Human Services, under the Viral Hepatitis Prevention and Control (CFDA 93.270) federal grant program. The award aims to strengthen public health systems and services through national partnerships to improve and protect the nation's health, specifically focusing on the public health workforce at state, local, and...

The Virginia State Board of Health, through its Office of Emergency Preparedness Division, has been awarded a $14,375,039 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Non-Governmental Organization Based program (CFDA 93.939). The award will fund a comprehensive and integrated HIV surveillance and prevention program in Virginia to prevent new infections, improve health outcomes for people living with HIV, and reduce related...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $9,349,159 Cooperative Agreement (CFDA 93.940 - HIV Prevention Activities Health Department Based) to the Alabama Department of Public Health (ADPH) to provide a collaborative mechanism to identify and address the most significant HIV needs of persons with HIV, allocate resources effectively and appropriately to the greatest HIV burdened communities. The award period is from August 1, 2024 to May 31, 2029. As the recipient, ADPH...

The federal Project Grant award of $483,194 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to define the protective CD4+ T cell signature that supports effective CD8+ T cell immunity against hepatitis C virus (HCV) infection. The research will leverage historical blood and liver samples from chimpanzees to characterize HCV-specific CD4+ T cell responses using single-cell...

This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...

The City of Houston, Department of Health and Human Services (HHD) was awarded a $36,072,220 Cooperative Agreement from the Centers for Disease Control and Prevention (CDC) under the HIV Prevention Activities Non-Governmental Organization Based program (CFDA 93.939). The award will fund enhanced HIV surveillance and prevention activities in the Houston metropolitan area from August 1, 2024 to May 31, 2029. Key initiatives include: Increasing and expanding HIV testing through community-based...

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $3,303,652 Cooperative Agreement under the HIV Prevention Activities Health Department Based program (CFDA 93.940) to the Virgin Islands Department of Health Group. The funding will support comprehensive HIV prevention, surveillance, and treatment efforts in the U.S. Virgin Islands over a period of 5 years, from August 2024 to May 2029. The key products and services to be delivered include: Enhancing HIV surveillance systems...

The National Institute on Drug Abuse (NIDA) awarded a $707,647 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Weill Medical College of Cornell University to conduct research on universal hepatitis C virus (HCV) screening during pregnancy. The project aims to: 1) determine if revised HCV testing guidelines led to increased testing rates among pregnant women compared to non-pregnant women; 2) assess if the guidelines increased postpartum HCV linkage to care, treatment,...

The Project Grant award R01AI179309 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a 5-year, $762,072 translational research project to discover a safe and effective long-acting antiviral therapy for hepatitis B (HBV). The research aims to leverage expertise and collaboration to transform existing short-acting oral antiviral drugs into a new long-acting injectable HBV therapy. Key goals...

The National Alliance For Hispanic Health was awarded a $750,000 Project Grant from the Centers for Disease Control and Prevention (CDC) Investigations and Technical Assistance program (CFDA 93.283) for the "LIVERWISE: HEALTHY LIVER, HEALTHY LIFE!" initiative. This 3-year grant, awarded on September 30, 2024, aims to improve liver health outcomes within the Hispanic community through targeted interventions and technical assistance programs. The grant supports the organization's...